Vulvar Langerhans cell histiocytosis: a case report

Vulvar Langerhans cell histiocytosis: a case report

 

Nadia Khoummane^1,&, Cyriane Guimeya², Dominique Lipombi³, François Gielen³

 

¹Department of Gynecology and Obstetrics, Oncology and High Risk Pregnancies- Maternité Souissi, Rabat, Morocco, ²Université libre de Bruxelles, Department Of Gynecology And Obstetrics, CHR de la Haute Senne, Soignies, Belgium, ³Department Of Gynecology And Obstetrics, CHR de la Haute Senne, Soignies, Belgium

 

 

^&Corresponding author
Nadia Khoummane, Department of Gynecology and Obstetrics, Oncology and High Risk Pregnancies- Maternité Souissi, Rabat, Morocco et 18, rue Moulay Rachid n°5 Hassan Rabat, Morocco

 

 

 

 

Langerhans cell histiocytoses (LCH) are a rare group of disorders that comprise a large spectrum of diseases initially known as histiocytosis X. They present as a clonal neoplastic proliferation of Langerhans type cells. Three main clinical manifestations of Langerhans cell histiocytosis have been identified (Letterer-Siwe disease, Hand-Schuller-Christian disease and Hashimoto-Pritzker disease) but many intermediate and acute forms of the disease have been described. They vary from a local invasion requiring local treatment (60%) to an acute, more disseminated type. Genital LCH as the unique manifestation of this disease is rare. We present a case of a woman with LCH affecting solely the vulva.

 

 

The patient is a 47 year old, with no significant past medical history, presenting since 2009 with a perineal lesion for which a histopathological examrevealeda perineal granuloma. The patient sought consultation in June 2012 with the same complaint: a vulvar lesion for which she was operated a month later in July 2012. The lesion was excised, sent to the lab and the diagnosis of Langerhans cell histiocytosis surfaced (Figure 1, Figure 2, Figure 3, Figure 4, Figure 5). In this context, in order to determine if the histiocytosis is localized at a gynecological or systemic level, the patient underwent blood tests, a 24h urine collection, a chest and abdominal CT scan and a bone scintigraphy. Blood tests were within normal limits except for a slight eosinophilia (430/mm³). Renal function, hemogramme, liver function tests were all normal. We noticed minimal elevation in alkaline phosphatase reaching 260 U/l. Protein electrophoresis was in favor of an inflammation with elevated alpha-2 globulins: erythrocyte sedimentation rate was at 69mm/H with a normal C-reactive protein measuring 0.19mg/dl. Thyroid hormone levels as well as LH, FSH, Prolactin, cortisol, were all within normal limits. Urine osmolarity was normal and chest/abdominal CT scan was unremarkable. Bone scintigraphy did not show any specific lesion. There was no evidence of disease beyond the vulva. After working up the patient, we concluded to the diagnosis of Langerhans cell histiocytosis located in the vulvar area.

 

 

Langerhans cells are peripheral dendritic antigen processing cells of bone marrow origin. They are found throughout the body but primarily in the stratum spinosum of the epidermis [1]. They play an important role in localized immune response to antigen.

Langerhans cell histiocytosis (LCH) is a rare disorder characterized by abnormal proliferation of Langerhans cells.The Histiocyte Society classifies LCH as Single System LCH (SS-LCH) or Multisystem LCH (MS-LCH) depending on the extent and localization of disease [2]. For diagnosis to be made, presence of Birbeck granules by electron microscopy, protein S-100 as well as CD1 antibodies in the histiocytic cells of the lesion must be found [3].

The pathogenesis of the disease still remains debatable. Two main theories emerge: neoplasticversus reactive processes. The first is supported by the fact that the proliferation of Langerhans cells appears to be monoclonal in nature due to somatic changes in tumor suppressor genes [4] as well as the positive response to chemotherapeutic drugs. The role of cytokines and interleukins has not yet been understood. TNF-alpha appears to play an important role [5] as well as E-cadherin, whose absence allows dissemination of LCH from a localized lesion in the skin [6]. The second has its roots from the fact that some cases resolve spontaneously [7], the extensive secretion of multiple cytokines by dendritic cells (a phenomenon known as cytokine storm) in the affected tissue, favorable prognosis and relatively good survival rate in patients without organ dysfunction or risk organ involvement [8].

The clinical manifestations of LCH are diverse. They range from non-specific inflammatory responses such as fever, fatigue, to more specific symptoms depending on the organ involved. In our case, genital lesions are mucocutaneous in nature. They are erythematous plaques often ulcerated. Biopsy of the affected area should be performed in order to start adequate management.

Due to the scarcity of reported cases of vulvar Langerhans cell histiocytosis, there are no gold standard or guidelines of treatment. Many regimens have been suggested ranging from local surgery, topical corticosteroids to chemotherapeutic agents [9]. The use of nitrogen mustard has also been reported and produced satisfactory responses [10].

Thalidomide, a hypnosedative drug has been used successfully for treatment of localized LCH such as perianal lesions [11], genital and disseminated skin lesions [12]. An initial dose of 100mg per day is sufficient until the lesions have healed followed by a maintenance dose of 50mg/day [13,14]. Treatment is not definitive and has been associated with recurrence.

Finally, professionals should keep in mind not to treat straightforwardly lesions of the genital tract as simple sexually transmitted diseases. Chronic, atypical genital lesions seen in women need to be worked up and dealt with accordingly.

 

 

Langerhans cell histiocytosis of the vulva remains a rare disorder with very few described cases in the literature. Two main subtypes are described by the histiocyte society, which are single and multi system LCH [2]. The pathogenesis still remains under investigation. Whether it is neoplastic or reactive is yet to be proved. Exposing the presence of Birbeck granules, protein S-100 and CD1 antibodies makes diagnosis easier. Treatments of Langerhans cell histiocytosis of the vulva are numerous. Up to date, thalidomide is thought to deliver satisfactory results although it does not exclude the risk of recurrence.

 

 

The authors declared they have no conflicts of interest.

 

 

All the authors have homogenously contributed to the submission of this report. All the authors have read and approved the final version of the manuscript.

 

 

Figure 1: macroscopic aspect of vulvar langerhans cell histiocytosis

Figure 2: macroscopic aspect of vulvar langerhans cell histiocytosis

Figure 3: microscopic aspect of vulvar langerhans cell histiocytosis ( lens 40)

Figure 4: microscopic aspect of vulvar langerhans cell histiocytosis: immunolabelling CD 1a ( lens 20)

Figure 5: microscopic aspect of vulvar langerhans cell histiocytosis: immunolabelling S 100 ( lens 20)

 

 

1. Young Barbara, Heath John W. Wheater's Functional Histology (4th ed). 2000. London, England. Churchill Livingstone.


2. The Histiocyte Society. Welcome to our Society. 2011. Available from: http://www.histiocytesociety.org. viewed August 2013.


3. Gadner H, Grois N. Histiocytosis Syndromes, in Fitzpatrick TB, Elsen AZ, Wolff K, et al, eds. Dermatology in General Medicine, 4th ed. 199 New York, McGraw-Hill Inc. PubMed | Google Scholar


4. Willman CL, Busque l, Griffith BB. Langerhans’ cell histiocytosis (Histiocytosis X): a clonal proliferative disease. N Engl J Med 1994 Jul 21;331(3):154-60. Google Scholar


5. Foss HD, Herbst H, Araujo I, Thomas C, Fraitag S, Prost Y, Brousse N. Monokine expression in Langerhans’ cell histiocytosis and sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease). J Pathol. 1996 May;179(1):60-5. PubMed | Google Scholar


6. Mcclain K, Jin H, Gresik V, Favara B. Langerhans’ cell histiocytosis. Lack of a viral etiology. Am J Hematol. 1994 Sep;47(1):16-20. PubMed | Google Scholar


7. Broadbent V, Pritchard J, Davies EG, et al. Spontaneous remission of multi-system histiocytosis X. Lancet. 1984 Feb 4;1(8371):253-4. PubMed | Google Scholar


8. De Filippi P, Badulli C, Cuccia M, et al.: Specific polymorphisms of cytokine genes are associated with different risks to develop single-system or multi-system childhood Langerhans cell histiocytosis. Br J Haematol. 2006;132 (6): 784-7. PubMed | Google Scholar


9. Axiotis CA, Merino JM, Duray PH. Langerhans cell histiocytosis of the female genital tract. Cancer. 1991 Mar 15;67(6):1650-60. PubMed | Google Scholar


10. Verret JL, Hadet M, Brunet A, Elnekave FL, Avenel M. Histiocytose X avecgranulomee´osinophilepe´rianovulvaire. Effet favorable des applications locales de moustarde a l’azotesurlc`sionsanovulvaires. Ann Dermatol Venereol. 1985;112(2):165-6. PubMed | Google Scholar


11. Sander CS, Kaatz M, Elsner P. Successful treatment of cutaneous Langerhans cell histiocytosis with thalidomide. Dermatology. 2004;208(2):149-52. PubMed | Google Scholar


12. Li R, Lin T, Gu H, Zhou Z. Successful thalidomide treatment of adult solitary perianal Langerhans cell histiocytosis. Eur J Dermatol. 2010 May-Jun;20(3):391-2. PubMed | Google Scholar


13. Lair G, Marie I, Cailleux N, Blot E, Bouillié MC, Courville P, et al. Histiocytose langerhansienne de l’adulte : localisationscutanéomuqueuses régressives après traitement par thalidomide. Rev Med Interne. 1998 Mar;19(3):196-8. PubMed | Google Scholar


14. Meunier L, Marck Y, Ribeyre C, Meynadier J. Adulte cutaneous Langerhans cellhistiocytosis: remission with thalidomide treatment. Br J Dermatol. 1995 Jan;132(1):168. PubMed | Google Scholar